#China #Beijing #Keymed Biosciences #Kangyueda #CMG901

Keymed Biosciences 2025 Annual Results Announcement

Keymed Biosciences, a prominent name in the biopharmaceutical industry, has recently disclosed its financial results for the fiscal year 2025. This year has not only marked a significant milestone in terms of revenue accumulation but has also positioned Keymed as a dynamic player in the innovative healthcare market.

Revenue Growth and Key Product Sales

According to the annual report, Keymed achieved total revenues of approximately 720 million RMB in 2025, reflecting an impressive 67% increase compared to the previous year. A key contributor to this growth was the main product, Kangyueda®, which generated around 310 million RMB in sales. Additionally, collaborations with various partners accounted for approximately 410 million RMB of the overall revenue.

The consistent commitment to research and development (R&D) was evident, with around 720 million RMB allocated to R&D initiatives this past year. By December 31, 2025, the company's cash reserves stood at an impressive 1.96 billion RMB. This financial stability will undoubtedly aid in the continued development of innovative treatments.

Regulatory Approvals and Market Accessibility

A significant achievement for Keymed in 2025 was the approval of Kangyueda® for treating moderate to severe atopic dermatitis, chronic rhinosinusitis with nasal polyps, and seasonal allergic rhinitis by the National Medical Products Administration (NMPA). These approvals are groundbreaking as, since January 2026, all launched indications are now part of China’s National Reimbursement Drug List. This inclusion is expected to enhance the accessibility and affordability of treatments for a greater number of patients within China, enabling them to receive the necessary care.

During 2025, the sales revenue for Kangyueda® reached approximately 315 million RMB, further emphasizing its success in the market.

Licensing and Global Expansion

In a critical move, Keymed licensed CMG901 (also known as AZD0901), a first-of-its-kind antibody-drug conjugate targeting Claudin-18.2, to AstraZeneca for global development. In February 2026, the clinical trials for this product progressed as the first dose was administered to a participant, triggering a milestone payment for Keymed of 45 million USD. This activity marks a substantial step forward in Keymed's plans for global outreach and impact.

Moreover, CM336, a bispecific antibody targeting BCMA x CD3, was licensed to Ouro Medicines for global development, excluding Greater China. In a recent announcement, Ouro Medicines disclosed its impending merger with Gilead Sciences, a deal that could suggest a lucrative return for Keymed, potentially receiving around 320 million USD depending on shareholder agreements and milestone achievements.

Investment in Technology and Innovation

Keymed is also focused on advancing its technological capabilities through the establishment of numerous platforms aimed at drug discovery and development. These include an Antibody Discovery Platform, ADC Platform, BsAb TCE Platform, Oligonucleotide Platform, Small Molecule Platform, and a Platform for Antibodies Crossing the Blood-Brain Barrier. By leveraging the synergistic innovation capacities across these platforms, Keymed is set to continue delivering high-quality, innovative medicines to patients globally.

In summary, 2025 proved to be a landmark year for Keymed Biosciences, showcasing strong financial results and significant advancements in its product line. With its strategic licensing agreements and ongoing investment in R&D and technology, the company is well-positioned to make a substantial impact in the biopharmaceutical market, promising a healthier future for countless patients worldwide.